CIRCULATING miRNAs AS MARKERS FOR BREAST CANCER

摘要

The present invention is concerned with a method for diagnosing breast cancer in a subject comprising the steps of determining in a sample of a subject suspected to be afflicted with said breast cancer the amount of at least one miRNA or the amounts of at least the miRNAs of a combination of miRNAs selected from the group consisting of: (i) miR-801, (ii) miR-801 and miR-148b, (iii) miR-801 and miR-376c, (iv) miR-801 and miR-409-3p, (v) miR-801, miR-376c and miR-148b, (vi) miR-801, miR-409-3p and miR-376c, (vii) miR-801, miR-409-3p and miR- 148b, (viii) miR-801, miR-376c, miR-409-3p and miR-148b, (ix) miR-148b, (x) miR-409-3p, (xi) miR-376c, (xii) miR-376c and miR-409-3p, (xiii) miR-148b and miR-376c, (xiv) miR-148b and miR-409-3p, (xv) miR-148b, miR-376c and miR-409-3p;, (xvi) miR-127-3p, (xvii) miR-148b, (xvii) miR-376a, (xix) miR-376c, (xx) miR-409-3p, (xxi) miR-652, (xxii) miR-127-3p, miR-148b, miR-376a, miR-376c, miR-409-3p, miR-652, and miR-801, (xxiii) miR-127-3p, miR-148b, miR- 652, and miR-801, (xxiv) miR-376a, miR-148b, miR-652, and miR-801, (xxv) miR-376c, miR- 148b, miR-652, and miR-801, and (xxvi) miR-409-3p, miR-148b, miR-652, and miR-801 and comparing said amount with a reference or comparing said amounts with references, whereby breast cancer is to be diagnosed. The present invention is also concerned with methods for diagnosing metastasizing breast cancer in a subject and for determining the circulating tumor cell (CTC) status in a subject comprising the steps of (a) determining in a sample of a subject suspected to be afflicted with said metastasizing breast cancer the amount of at least one miRNA selected from the group consisting of: miR-801, miR-141, miR-200a, miR-200b, miR- 200c, miR-203, miR-210, miR-375, miR-142-3p, and miR-768-3p, and (b) comparing said amount with a reference or comparing said amounts with references. Furthermore the present invention is concerned with the use of the miRNAs of the invention for diagnosing breast cancer, metastasizing breast cancer, or for determining the CTC status in a subject. Moreover, the present invention is concerned with devices and kits for carrying methods of the invention.